NRG ONCOLOGY/RTOG 0921: A PHASE II STUDY OF POSTOPERATIVE INTENSITY MODULATED RADIATION THERAPY (IMRT) WITH CONCURRENT CISPLATIN AND BEVACIZUMAB FOLLOWED BY CARBOPLATIN AND PACLITAXEL FOR PATIENTS WITH ENDOMETRIAL CANCER

PURPOSE: To assess acute and late adverse events (AEs), overall survival (OS), pelvic failure (PF), regional failure, distant failure, and disease-free survival (DFS) in a prospective phase II clinical trial of bevacizumab (Bev) and pelvic intensity modulated radiation therapy (IMRT) with chemothera...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Viswanathan, Akila N., Moughan, Jennifer, Miller, Brigitte E., Xiao, Ying, Jhingran, Anuja, Portelance, Lorraine, Bosch, Walter, Matulonis, Ursula, Horowitz, Neil, Mannel, Robert S., Souhami, Luis, Erickson, Beth, Winter, Kathryn, Small, William, Gaffney, David
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4685031/
https://ncbi.nlm.nih.gov/pubmed/25847373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29337
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados